WebJun 4, 2024 · In connection with its agreement with Oberland Capital, Curis faces risks relating to the transfer and encumbrance of certain royalty and royalty-related payments on commercial sales of Erivedge ... WebTo be considered for Summer 2024 CURIS, you must follow these deadlines. January 10 - 29: Project entry. Faculty members enter project descriptions on the CURIS site. The …
Curis Reports Updated Data in Two Abstracts for CA-4948 …
WebDec 2, 2024 · On December 6, 2024, the Company filed a Current Report on Form 8-K (the "Report") disclosing that the Board of Directors ("Board") of Curis, Inc. (the "Company") elected John A. Hohneker, M.D., to serve as a class II director until the Company's 2024 Annual Meeting of Stockholders and thereafter until his successor is duly elected and … WebJun 11, 2024 · Cancer drug specialist Curis (CRIS 8.40%) had a Friday to forget. The biotech's share price took a nearly 37% hit after the company reported some disquieting news about a leading pipeline drug. chinese supermarket brighton
Curis Reports Inducement Grants Under NASDAQ Listing Rule …
WebMay 12, 2024 · Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of... WebApr 4, 2024 · LEXINGTON, Mass., April 4, 2024 - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's TakeAim Leukemia Phase 1/2a study … WebJun 11, 2024 · The reported data are from Curis's ongoing open-label, single arm Phase 1/2 dose escalation 3+3 study of orally administered CA-4948 monotherapy in adult patients … chinese supermarket bradwell abbey